How the FDA Mints All-New Millionaires
There’s a common trait that shows up in many of the best-performing biotech stocks of all time.
It’s called “fast-track” status.
Here’s the definition from the FDA’s website.
Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important new drugs to the patient earlier. Fast Track addresses a broad range of serious conditions.
Determining whether a condition is serious is a matter of judgment, but generally is based on whether the drug will have an impact on such factors as survival, day-to-day functioning, or the likelihood that the condition, if left untreated, will progress from a less severe condition to a more serious one. AIDS, Alzheimer’s, heart failure and cancer are obvious examples of serious conditions.
Needless to say, it takes a special medical innovation to receive the FDA’s fast-track designation. But when a company does receive it, amazing gains are possible for investors.
Let me tell you about a handful of lucky companies that have already received special FDA treatment.
Regeneron received special FDA status for several of its drugs, including its bestselling macular degeneration drug.
It went on to surge from around $5… to $540. That’s a 112-fold increase—an incredible 11,208% gain.
That’s good enough to turn a $5,000 stake into $560,400.
Double your investment and you’re looking at a million dollars and change.
As reported by The Wall Street Journal, Regeneron’s sky-high run minted 580 brand-new millionaires overnight.
The CEO said in one interview, “We’ve probably made more millionaires than any company in New York.”
Here’s another example, this time with Questcor.
Questcor received a special FDA status for Acthar, a drug designed to treat a devastating disease that affects infants.
Shares surged from 21 cents in 2007… to over $95 in 2014. That’s a 239-fold increase—a 23,955% gain.
Good enough to turn $5,000 into $1.19 million in less than seven years.
Now consider Jazz Pharmaceutical.
The company received special FDA status for JZP-8, a drug designed to control seizures in epilepsy patients.
The stock soared from 55 cents in 2009 to over $170 in 2014. A stunning 310-fold gain, more than 30,000%.
Good enough to turn $10,000 into over $3.1 million in less than six years.
But the most remarkable gains I’ve seen come from the biotech company Amgen, now one of the biggest in the world.
When two of its drugs received special FDA status, the stock went on to deliver unbelievable 178,119% gains… the biggest return I’ve ever seen on the market.
See the proof yourself…
It’s absolutely incredible.
According to Forbes, investors who put down a $100 stake in Amgen early, when it was just a startup, would now have shares worth more than $1.5 million.
The Los Angeles Business Journal reports the company’s investors are now known as the “Amgen millionaires.”
Many of these early retirees are even using their “stock-fueled wealth to become angel investors.”
That includes every single early employee, from sales reps to secretaries to managers.
Heck, even the company’s first dishwasher, who is now head of landscaping, became a millionaire.
All from Amgen stock options.
Genentech—the groundbreaking gene-splicing company—minted a similar group of millionaires.
Like Richard Scheller, a 26-year-old graduate student, whose $300 early investment made him $1.1 million overnight—a stunning 3,666-fold gain.
Or Herbert Boyer, a professor who saw his $500 investment turn into a one-day profit of $70 million.
Returns like these are simply unheard of anywhere in the financial markets—much less overnight.
Now, here’s the thing…
Everything I’ve seen tells me that a story,similar to the one’s I’ve just shared is developing.
As I detail in this presentation, one company in the cancer field has received fast-track status, and should be releasing important data at any moment now that could send shares soaring.
Click here now for the full details on this amazing story.